{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:42:18Z","timestamp":1774374138543,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T00:00:00Z","timestamp":1560556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T00:00:00Z","timestamp":1560556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amgen (Europe) GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00520-019-04858-2","type":"journal-article","created":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T12:02:48Z","timestamp":1560600168000},"page":"1151-1162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Management of bone health in patients with cancer: a survey of specialist nurses"],"prefix":"10.1007","volume":"28","author":[{"given":"Lawrence","family":"Drudge-Coates","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"van Muilekom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio C","family":"de la Torre-Montero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marsha","family":"van Oostwaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Niepel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bente Thoft","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,15]]},"reference":[{"issue":"7","key":"4858_CR1","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1136\/bmjqs-2016-005567","volume":"26","author":"LH Aiken","year":"2016","unstructured":"Aiken LH, Sloane D, Griffiths P, Rafferty AM, Bruyneel L, McHugh M, Maier CB, Moreno-Casbas T, Ball JE, Ausserhofer D, Sermeus W, RN4CAST Consortium (2016) Nursing skill mix in European hospitals: cross-sectional study of the association with mortality, patient ratings, and quality of care. BMJ Qual Saf 26(7):559\u2013568","journal-title":"BMJ Qual Saf"},{"key":"4858_CR2","unstructured":"Alibhai S, Zukotynski K, Walker-Dilks C, Emmenegger U, Finelli A, Morgan S et al (2016) Bone health and bone-targeted therapies for prostate cancer. Cancer Care Ontario \nhttps:\/\/www.cancercareontario.ca\/en\/guidelines-advice\/types-of-cancer\/31716\n\n. Accessed 28 May 2019"},{"key":"4858_CR3","unstructured":"Amgen (2017) XGEVA (denosumab). Summary of product characteristics. Amgen Europe, Breda, NL. \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002173\/WC500110381.pdf\n\n. Accessed 28 May 2019"},{"key":"4858_CR4","unstructured":"Amgen (2017) Prolia (denosumab). Summary of product characteristics. Amgen Europe, Breda, NL. \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001120\/WC500093526.pdf\n\n. Accessed 28 May 2019"},{"issue":"2","key":"4858_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.pec.2005.07.008","volume":"62","author":"C Arving","year":"2006","unstructured":"Arving C, Sjoden PO, Bergh J, Lindstrom AT, Wasteson E, Glimelius B et al (2006) Satisfaction, utilisation and perceived benefit of individual psychosocial support for breast cancer patients \u2013 a randomised study of nurse versus psychologist interventions. Patient Educ Couns 62(2):235\u2013243","journal-title":"Patient Educ Couns"},{"issue":"34","key":"4858_CR6","doi-asserted-by":"publisher","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23(34):8580\u20138587","journal-title":"J Clin Oncol"},{"issue":"4","key":"4858_CR7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48(4):677\u2013692","journal-title":"Bone"},{"key":"4858_CR8","unstructured":"Campbell P, Kelly D, Charalambous A, Torrens C, Domenech-Climent N, Freitas J et al (2016) Recognising European Cancer Nursing (RECaN): a systematic review and metaanalysis of the evidence of effectiveness and value of cancer nursing. PROSPERO International Prospective Register of Systematic Reviews \nhttps:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?RecordID=48760\n\n ID=CRD42016048760 Accessed 28 May 2019"},{"issue":"12","key":"4858_CR9","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1007\/s00520-015-2887-2","volume":"23","author":"C Campbell-Baird","year":"2015","unstructured":"Campbell-Baird C, Harrelson S, Frey G, Balakumaran A (2015) Clinical efficacy of denosumab versus bisphosphonates for the prevention of bone complications: implications for nursing. Support Care Cancer 23(12):3625\u20133632","journal-title":"Support Care Cancer"},{"issue":"8","key":"4858_CR10","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/bjc.2013.568","volume":"109","author":"J Cockle-Hearne","year":"2013","unstructured":"Cockle-Hearne J, Charnay-Sonnek F, Denis L, Fairbanks HE, Kelly D, Kav S, Leonard K, van Muilekom E, Fernandez-Ortega P, Jensen BT, Faithfull S (2013) The impact of supportive nursing care on the needs of men with prostate cancer: a study across seven European countries. Brit J Cancer 109(8):2121\u20132130","journal-title":"Brit J Cancer"},{"issue":"8","key":"4858_CR11","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(8 Suppl):1588\u20131594","journal-title":"Cancer"},{"issue":"6","key":"4858_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrrheum.2013.36","volume":"9","author":"RE Coleman","year":"2013","unstructured":"Coleman RE, Rathbone E, Brown JE (2013) Management of cancer treatment-induced bone loss. Nat Rev Rheumatol 9(6):365\u2013374","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 3","key":"4858_CR13","doi-asserted-by":"publisher","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","volume":"25","author":"R Coleman","year":"2014","unstructured":"Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J (2014) Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 25(Suppl 3):iii124\u2013iii137","journal-title":"Ann Oncol"},{"issue":"9","key":"4858_CR14","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/leu.2009.89","volume":"23","author":"M Dimopoulos","year":"2009","unstructured":"Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O et al (2009) International Myeloma Working Group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 23(9):1545\u20131556","journal-title":"Leukemia"},{"key":"4858_CR15","unstructured":"EAN (2015) Accreditation book: criteria and procedure for accreditation of educational activities in Europe. Brussels: European Accreditation Network for Educational Activities"},{"key":"4858_CR16","unstructured":"FDA (2017) Prolia prescribing information. Food and Drug Administration, USA. \nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125320s181lbl.pdf\n\n. Accessed 28 May 2019"},{"issue":"4","key":"4858_CR17","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1188\/08.ONF.709-713","volume":"35","author":"MI Fitch","year":"2008","unstructured":"Fitch MI, Maxwell C (2008) Bisphosphonate therapy for metastatic bone disease: the pivotal role of nurses in patient education. Oncol Nurs Forum 35(4):709\u2013713","journal-title":"Oncol Nurs Forum"},{"issue":"Suppl 3","key":"4858_CR18","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2013.0215","volume":"11","author":"JR Gralow","year":"2013","unstructured":"Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar R, Litsas G, McKay R, Podoloff DA, Srinivas S, van Poznak CH (2013) NCCN Task Force report: bone health in cancer care. J Natl Compr Cancer Netw 11(Suppl 3):S1\u2013S50 quiz S51","journal-title":"J Natl Compr Cancer Netw"},{"issue":"4","key":"4858_CR19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/pcan.2016.26","volume":"19","author":"LE Howard","year":"2016","unstructured":"Howard LE, De Hoedt AM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR et al (2016) Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer? Prostate Cancer Prostatic Dis 19(4):380\u2013384","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"4858_CR20","doi-asserted-by":"publisher","first-page":"e12490","DOI":"10.1111\/ecc.12490","volume":"26","author":"T Lebret","year":"2017","unstructured":"Lebret T, Casas A, Cavo M, Woll PJ, Deleplace C, Kennedy C, Schoen P, Jackisch C (2017) The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies \u2013 a European survey. Eur J Cancer Care (Engl) 26(4):e12490. \nhttps:\/\/doi.org\/10.1111\/ecc.12490","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"5","key":"4858_CR21","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","volume":"88","author":"A Lipton","year":"2000","unstructured":"Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082\u20131090","journal-title":"Cancer"},{"issue":"4","key":"4858_CR22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/tbj.12431","volume":"21","author":"D Luftner","year":"2015","unstructured":"Luftner D (2015) Clinical practice guidelines for breast cancer: current limitations. Breast J 21(4):450\u2013453","journal-title":"Breast J"},{"key":"4858_CR23","unstructured":"NICE (2014) Prostate cancer: diagnosis and management. CG175. National Institute for Health and Care Excellence. \nhttps:\/\/www.nice.org.uk\/guidance\/cg175\n\n. Accessed 28 May 2019"},{"key":"4858_CR24","unstructured":"Novartis (2017) Zometa (zoledronic acid for injection). Summary of product characteristics. Novartis Europharm Ltd, Camberley, UK. \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000336\/WC500051730.pdf\n\n. Accessed 28 May 2019"},{"key":"4858_CR25","unstructured":"Novartis (2017) Aclasta. Summary of product characteristics. Novartis Europharm Ltd, Camberley, UK. \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000595\/WC500020940.pdf\n\n. Accessed 28 May 2019"},{"issue":"11","key":"4858_CR26","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M, Zoledronic Acid Prostate Cancer Study Group (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96(11):879\u2013882","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"4858_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.nedt.2013.01.017","volume":"33","author":"KU Satu","year":"2013","unstructured":"Satu KU, Leena S, Mikko S, Riitta S, Helena LK (2013) Competence areas of nursing students in Europe. Nurse Educ Today 33(6):625\u2013632","journal-title":"Nurse Educ Today"},{"issue":"1","key":"4858_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","volume":"24","author":"AT Stopeck","year":"2016","unstructured":"Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Mart\u00edn M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A (2016) Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 24(1):447\u2013455","journal-title":"Support Care Cancer"},{"issue":"3","key":"4858_CR29","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1080\/07347332.2011.563342","volume":"29","author":"J Sussman","year":"2011","unstructured":"Sussman J, Howell D, Bainbridge D, Brazil K, Pyette N, Abbasi S, Whelan T (2011) The impact of specialized oncology nursing on patient supportive care outcomes. J Psychosoc Oncol 29(3):286\u2013307","journal-title":"J Psychosoc Oncol"},{"key":"4858_CR30","unstructured":"Team NNCA (2010) Excellence in cancer care: the contribution of the clinical nurse specialist. \nhttps:\/\/www.macmillan.org.uk\/documents\/aboutus\/commissioners\/excellenceincancercarethecontributionoftheclinicalnursespecialist.pdf\n\n. Accessed 28 May 2019"},{"issue":"Suppl 1","key":"4858_CR31","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/S1040-8428(11)70004-X","volume":"77","author":"E Terpos","year":"2011","unstructured":"Terpos E, Dimopoulos MA, Berenson J (2011) Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. Crit Rev Oncol Hematol 77(Suppl 1):S13\u2013S23","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"4858_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.7257\/1053-816X.2016.36.1.22","volume":"36","author":"B Turner","year":"2016","unstructured":"Turner B, Ali S, Drudge-Coates L, Pati J, Nargund V, Wells P (2016) Skeletal health part 2: development of a nurse practitioner bone support clinic for urologic patients. Urol Nurs 36(1):22\u201326","journal-title":"Urol Nurs"},{"key":"4858_CR33","first-page":"751","volume-title":"Encyclopedia of survey research methods","author":"A Villar","year":"2008","unstructured":"Villar A (2008) Response bias. In: Lavrakas PJ (ed) Encyclopedia of survey research methods. Sage, Thousand Oaks, CA, pp 751\u2013752"},{"issue":"2","key":"4858_CR34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","volume":"129","author":"M Yong","year":"2011","unstructured":"Yong M, Jensen AO, Jacobsen JB, Norgaard M, Fryzek JP, Sorensen HT (2011) Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999\u20132007). Breast Cancer Res Treat 129(2):495\u2013503","journal-title":"Breast Cancer Res Treat"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04858-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-04858-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04858-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T23:12:06Z","timestamp":1592089926000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-04858-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,15]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["4858"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-04858-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,15]]},"assertion":[{"value":"25 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"LD-C has received honoraria from Amgen, Astellas, Ferring, Ipsen and Novartis. EVM has received honoraria from Sanofi. JCTM and MvO have nothing to disclose. KL has received honoraria from Amgen. DN is an employee of Amgen and holds stock in Amgen. BTJ has received honoraria from Pierre Fabre and Wellspect. Medical writing support was funded by Amgen (Europe) GmbH. The authors declare that there were no conflicts of interest in the preparation of the questionnaire or the inclusion of participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of potential conflicts of interest"}},{"value":"All procedures were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Due to the nature of the research with data collected via an anonymised online survey, informed consent was not required but was implicit in participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}